DE69535206D1 - Das einbringen von nukleinsäuremolekülen in schleimhautgewebe - Google Patents
Das einbringen von nukleinsäuremolekülen in schleimhautgewebeInfo
- Publication number
- DE69535206D1 DE69535206D1 DE69535206T DE69535206T DE69535206D1 DE 69535206 D1 DE69535206 D1 DE 69535206D1 DE 69535206 T DE69535206 T DE 69535206T DE 69535206 T DE69535206 T DE 69535206T DE 69535206 D1 DE69535206 D1 DE 69535206D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- methods
- introduction
- tissue
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/357,398 US6348449B1 (en) | 1993-09-21 | 1994-12-16 | Methods of inducing mucosal immunity |
US357398 | 1994-12-16 | ||
PCT/US1995/016206 WO1996018390A1 (en) | 1994-12-16 | 1995-12-15 | Delivery of nucleic acid molecules to mucosal tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69535206D1 true DE69535206D1 (de) | 2006-10-12 |
DE69535206T2 DE69535206T2 (de) | 2007-07-12 |
Family
ID=23405416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535206T Expired - Lifetime DE69535206T2 (de) | 1994-12-16 | 1995-12-15 | Das einbringen von nukleinsäuremolekülen in schleimhautgewebe |
Country Status (10)
Country | Link |
---|---|
US (3) | US6348449B1 (de) |
EP (1) | EP0796104B1 (de) |
AT (1) | ATE337791T1 (de) |
AU (1) | AU701208B2 (de) |
CA (1) | CA2208524C (de) |
DE (1) | DE69535206T2 (de) |
DK (1) | DK0796104T3 (de) |
ES (1) | ES2273340T3 (de) |
PT (1) | PT796104E (de) |
WO (1) | WO1996018390A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348449B1 (en) * | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US6630455B1 (en) * | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
FR2751223B1 (fr) | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
DE69835525T2 (de) * | 1997-03-12 | 2007-03-08 | Idera Pharmaceuticals, Inc., Cambridge | Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden |
US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
US6821955B2 (en) * | 2000-04-07 | 2004-11-23 | Baylor College Of Medicine | Macroaggregated protein conjugates as oral genetic immunization delivery agents |
WO2002013861A2 (en) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Method and composition for altering a t cell mediated pathology |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
JP2002280463A (ja) * | 2001-03-16 | 2002-09-27 | Toshiba Corp | 半導体装置及びその製造方法 |
US7943146B2 (en) * | 2001-12-21 | 2011-05-17 | Myrexis, Inc. | Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface |
US7461046B2 (en) * | 2002-02-07 | 2008-12-02 | The University Of Utah Research Foundation | Method for creating and using a treatment protocol |
US20040138156A1 (en) * | 2002-02-26 | 2004-07-15 | Schneider Michael C | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
CN1756569A (zh) * | 2002-12-27 | 2006-04-05 | 印屈根治疗学股份有限公司 | 增生性病损中乳头瘤病毒和致癌原转化细胞的p53治疗 |
EP1638587A4 (de) | 2003-02-14 | 2007-04-18 | Univ Missouri | Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung |
US20060205070A1 (en) * | 2004-01-13 | 2006-09-14 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | HIV TEV compositions and methods of use |
AU2007285472B2 (en) * | 2006-03-30 | 2013-10-24 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
US20080031872A1 (en) * | 2006-08-02 | 2008-02-07 | Karp Nelson M | HIV immunogenic composition and method of administration |
US20080112974A1 (en) * | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
EP2668501B1 (de) | 2011-01-27 | 2019-06-12 | Invisible Sentinel, Inc. | Analytnachweisvorrichtungen, multiplex- und tischplattenvorrichtungen für den nachweis von analyten und verwendungen davon |
CN104919055B (zh) | 2012-03-09 | 2018-06-19 | 因威瑟堡善迪诺有限公司 | 用单一信号检测多种分析物的方法和组合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3948787A (en) * | 1973-05-04 | 1976-04-06 | Monsanto Company | Capacitor and dielectric impregnant composition therefor |
GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5468485A (en) * | 1987-06-04 | 1995-11-21 | Washington University | Avirulent microbes and uses therefor |
US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
US5185254A (en) | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
DE69032284T2 (de) | 1989-03-21 | 1998-10-08 | Vical, Inc., San Diego, Calif. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
WO1991012329A2 (en) | 1990-02-12 | 1991-08-22 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
DK0584348T3 (da) | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
WO1993023552A1 (en) | 1992-05-21 | 1993-11-25 | Government Of The United States As Represented By Secretary Department Of Health And Human Services | Targeting gene expression to living tissue using jet injection |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
GB9223816D0 (en) | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5981505A (en) * | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
AU675702B2 (en) | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
CA2153243A1 (en) | 1993-01-27 | 1994-08-18 | Harold E. Selick | Compositions and methods for transdermal drug delivery |
NZ265818A (en) | 1993-04-19 | 1997-09-22 | Medisorb Technologies Internat | Compositions of nucleic acids encapsulated with molecules that facilitate uptake and integration into living cells |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5804566A (en) * | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US6348449B1 (en) * | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
WO1995011701A1 (en) | 1993-10-26 | 1995-05-04 | Syntello, Inc. | Inhibition of hiv mucosal infection |
JPH09512177A (ja) | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
-
1994
- 1994-12-16 US US08/357,398 patent/US6348449B1/en not_active Expired - Lifetime
-
1995
- 1995-12-15 DE DE69535206T patent/DE69535206T2/de not_active Expired - Lifetime
- 1995-12-15 AU AU45169/96A patent/AU701208B2/en not_active Ceased
- 1995-12-15 WO PCT/US1995/016206 patent/WO1996018390A1/en active IP Right Grant
- 1995-12-15 AT AT95943781T patent/ATE337791T1/de active
- 1995-12-15 PT PT95943781T patent/PT796104E/pt unknown
- 1995-12-15 DK DK95943781T patent/DK0796104T3/da active
- 1995-12-15 CA CA2208524A patent/CA2208524C/en not_active Expired - Fee Related
- 1995-12-15 EP EP95943781A patent/EP0796104B1/de not_active Expired - Lifetime
- 1995-12-15 ES ES95943781T patent/ES2273340T3/es not_active Expired - Lifetime
-
2002
- 2002-02-14 US US10/076,900 patent/US7220728B2/en not_active Expired - Fee Related
-
2007
- 2007-05-21 US US11/751,569 patent/US8536145B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0796104B1 (de) | 2006-08-30 |
EP0796104A1 (de) | 1997-09-24 |
AU701208B2 (en) | 1999-01-21 |
US6348449B1 (en) | 2002-02-19 |
US7220728B2 (en) | 2007-05-22 |
CA2208524A1 (en) | 1996-06-20 |
US20020142987A1 (en) | 2002-10-03 |
DE69535206T2 (de) | 2007-07-12 |
AU4516996A (en) | 1996-07-03 |
ATE337791T1 (de) | 2006-09-15 |
US20080139494A1 (en) | 2008-06-12 |
CA2208524C (en) | 2012-03-13 |
EP0796104A4 (de) | 1998-01-07 |
ES2273340T3 (es) | 2007-05-01 |
DK0796104T3 (da) | 2007-01-08 |
US8536145B2 (en) | 2013-09-17 |
WO1996018390A1 (en) | 1996-06-20 |
PT796104E (pt) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535206D1 (de) | Das einbringen von nukleinsäuremolekülen in schleimhautgewebe | |
BR0106682A (pt) | Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo | |
BR9809914A (pt) | Genes de moracella receptores de lactoferrina | |
ES2010727A6 (es) | Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv. | |
ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
ES2062993T3 (es) | Factor de crecimiento humano i semejante a la preproinsulina. | |
DE69840333D1 (de) | 2-m übergang des zellzyklus | |
ATE338113T1 (de) | Transferrin-rezeptor gene von haemophilus | |
KR970701199A (ko) | 성장 정지 호메오박스 유전자(Growth Arrest Homeobox Gene) | |
DK0909323T3 (da) | Helicobacter pylori-bakterioferritin | |
ATE374817T1 (de) | Krebszellen-impfstoff | |
ATE189961T1 (de) | Impfstoff gegen mycobakterielle infektionen | |
DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
WO1993017031A3 (en) | Nucleic acids encoding dystrophin-associated proteins | |
DE69728897D1 (de) | Saeugetierchemokine | |
KR950701345A (ko) | 엘라스타제 저해활성을 갖는 신규 펩티드 및 그의 제조방법 | |
BR9608482A (pt) | Genes receptores de transferrina | |
AR025482A1 (es) | Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m | |
EP0841399A3 (de) | Menschliche Fin-1 Nukleinsäure (eine Caspase) und Proteinsequenzen und Verwendung davon | |
DK595187A (da) | Minactivin og fremgangsmaade til fremstilling deraf | |
ATE162853T1 (de) | Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung | |
DK551786D0 (da) | Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed | |
PT914417E (pt) | Dnase ii humana | |
PT88913A (pt) | Processo para a preparacao da proteina pp4-x anticoagulante | |
WO2004065554A3 (en) | Human saa3 nucleic acid molecule, protein, and methods of use for same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |